# EDGAR Filing Document

**Accession Number:** 0001509745
**File Stem:** 0001104659-25-114713
**Filing Date:** 2025-11
**Character Count:** 13701
**Document Hash:** 3bc056097c6a193778f24ef143623b76
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-114713.hdr.sgml**: 20251120

**ACCESSION NUMBER**: 0001104659-25-114713

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20251111

**FILED AS OF DATE**: 20251120

**DATE AS OF CHANGE**: 20251120

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** McEvoy William Patrick III
- **CENTRAL INDEX KEY:** 0002092596

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37990
- **FILM NUMBER:** 251504491

**MAIL ADDRESS:**
- **STREET 1:** 222 E 34TH ST, APT 2401
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10016
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CYPHERPUNK TECHNOLOGIES INC.
- **CENTRAL INDEX KEY:** 0001509745
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 274412575
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 47 THORNDIKE STREET
- **STREET 2:** SUITE B1-1
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142
- **BUSINESS PHONE:** 617 252 4343

**MAIL ADDRESS:**
- **STREET 1:** 47 THORNDIKE STREET
- **STREET 2:** SUITE B1-1
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02142

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LEAP THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20160818

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Dekkun Corp
- **DATE OF NAME CHANGE:** 20110107

## Ex-24

**Exhibit 24**

**LEAP THERAPEUTICS, INC.**

**POWER OF ATTORNEY**

Know all by these present, that the undersigned hereby constitutes and appoints Douglas Onsi with full power of substitution, the undersigned's true and lawful attorney-in-fact to, with respect to Leap Therapeutics, Inc., a Delaware corporation (the "Company"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to
the U.S. Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary
or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section
16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or any rule or regulation of the SEC;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) execute, for and on behalf of the undersigned, in the undersigned's capacity as an officer, director
and/or more than 10% stockholder, if applicable, of the Company, Forms 3, 4, and 5, in accordance with Section 16 of the Exchange Act
and the rules promulgated thereunder;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable
to complete and execute any such Form 3, 4, or 5, complete and execute any amendment or amendments thereto, and timely file such form
with the SEC and any stock exchange or similar authority; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of
such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that
the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form
and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to each such attorney-in-fact. This Power of Attorney supersedes any prior power of attorney granted by the undersigned with respect to Forms 3, 4, and 5 with respect to the Company's securities.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 9th day of November, 2025.

---

| |
|:---|
| */s/* William McEvoy |
| William McEvoy |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>McEvoy William Patrick III<br><sub>(Last) (First) (Middle)</sub><br>C/O CYPHERPUNK TECHNOLOGIES INC.<br>47 THORNDIKE STREET SUITE B1-1<br><sub>(Street)</sub><br>CAMBRIDGE, MA 02141<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>CYPHERPUNK TECHNOLOGIES INC. [ CYPH ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2025-11-11 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [X] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Chief Investment Officer_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Shares | 8283761 | I | See Notes<sup>(1)(2)(3)(4)(5)(6)</sup> |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Pre-Funded Warrants (right to buy) | <sup>(7)</sup> | <sup>(7)</sup> | Common Shares | 75448618 | <sup>(7)</sup> | I | See Notes<sup>(1)(2)(3)(4)(5)(7)</sup> |
| Common Warrants (right to buy) | <sup>(8)</sup> | <sup>(8)</sup> | Common Shares | 57182378<sup>(1)(2)(3)</sup> | <sup>(8)</sup> | I | See Notes<sup>(1)(2)(3)(4)(5)(8)</sup> |

---

### Footnotes:

(1) On October 6, 2025, Cypherpunk Technologies Inc. (f/k/a Leap Therapeutics, Inc.) (the "Company") entered into a securities purchase agreement (the "Securities Purchase Agreement") for the private placement of an aggregate of (i) 15,212,311 shares of Company common stock, par value $0.001 per share ("Common Stock"), at an offering price of $0.52064 per share, (ii) pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 80,768,504 shares of Common Stock (the "Pre-Funded Warrant Shares") at an offering price of $0.51964 per Pre-Funded Warrant, exercisable at the exercise price of $0.001 per Pre-Funded Warrant Share, and (iii) common warrants (the "Common Warrants") to purchase up to an aggregate of 71,985,605 shares of Common Stock (the "Common Warrant Shares"), exercisable at the exercise price of $0.5335 per Common Warrant Share (the "Private Placement"). The Private Placement closed October 8, 2025. (Continued in following footnote).

(2) (Continued from prior footnote) In connection with the Private Placement, Winklevoss Treasury Investments, LLC, a Delaware limited liability company ("WTI") acquired an aggregate of (i) 8,283,761 shares of Common Stock, (ii) Pre-Funded Warrants to purchase up to an aggregate of 75,448,618 Pre-Funded Warrant Shares, and (iii) Common Warrants to purchase up to an aggregate of 62,799,284 Common Warrant Shares (later reduced to 57,182,378 pursuant to the Assignment (defined below) (collectively, the "WTI Securities"), subject to beneficial ownership thresholds prohibiting beneficial ownership (as calculated in accordance with Section 13(d) of the Securities Exchange Act of 1933, as amended, and the rules and regulations promulgated thereunder) in excess of 19.99% of the issued and outstanding shares of Common Stock after giving effect to the Private Placement (the "Beneficial Ownership Limitation"), as may be adjusted downward from time to time. (Continued in following footnote).

(3) (Continued from prior footnote) Pursuant to information provided by WTI, the WTI Entities have assigned 5,616,906 of the 62,799,284 Common Warrants (the "Assignment"), reducing their reported beneficial ownership of the Common Warrants to 57,182,378.

(4) The WTI Securities are held by Winklevoss Capital Fund, LLC, a Delaware limited liability company, ("WCF"), WTI, Winklevoss Capital Management, LLC, a Delaware limited liability company ("WCM"), Mr. Tyler Howard Winklevoss ("Tyler Winklevoss"), and Mr. Cameron Howard Winklevoss ("Cameron Winklevoss" and, together with WCF, WTI, WCM and Tyler Winklevoss, the "WTI Entities"). Tyler Winklevoss and Cameron Winklevoss are the co-founders and managers of WCM. WCM is the manager of WCF, and WTI is a wholly owned subsidiary of WCF. (Continued in following footnote).

(5) (Continued from prior footnote) Mr. William McEvoy is the manager of WTI and Vice President of WCM. Mr. McEvoy disclaims beneficial ownership of the WTI Securities held by the WTI Entities, except to the extent of his pecuniary interest therein, if any. Mr. McEvoy was appointed to the Company's board of directors November 11, 2025, in connection with the Lead Investor Agreement, dated October 6, 2025, by and between the Company and WTI, as Lead Investor.

(6) Reflects Common Shares acquired pursuant to the Private Placement and consists of 8,283,761 shares of Common Stock held by the WTI Entities.

(7) Reflects Prefunded Warrants acquired pursuant to the Private Placement and consists of 75,448,618 Prefunded Warrants held by the WTI Entities, each exercisable for one share of Common Stock at the exercise price of $0.001 per Pre-Funded Warrant Share. The Pre-Funded Warrants are exercisable as of their date of issuance, however may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof (together with its affiliates) immediately following such exercise would exceed the Beneficial Ownership Limitation. The Pre-Funded Warrants are exercisable in cash or by means of a cashless exercise and will not expire until the date such Pre-Funded Warrants are fully exercised. Each Pre-Funded Warrant is subject to appropriate adjustment.

(8) Reflects Common Warrants acquired pursuant to the Private Placement, as adjusted by the Assignment, and consists of 57,182,378 Common Warrants held by the WTI Entities, each exercisable for one share of Common Stock at the exercise price of $.5335 per Common Warrant Share. Subject to the terms of the Waiver and Modification Agreement, dated November 19, 2025, by and between the Company and WTI, the Common Warrants are exercisable as of their date of issuance, however may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof (together with its affiliates) immediately following such exercise would exceed the Beneficial Ownership Limitation. The Common Warrants are exercisable in cash or by means of a cashless exercise and will not expire until the tenth anniversary of their date of issuance. Each Common Warrant is subject to appropriate adjustment.

**Remarks:**
Exhibit 24 - Power of Attorney

**Signature:** /s/ Douglas E. Onsi, as attorney-in-fact for the reporting person  
**Date:** 2025-11-20

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**